Primary prophylaxis of venous thromboembolism in surgical patients

Vascular and Endovascular Surgery

Volumn 42, Issue 3, 2008, Pages 205-216

  Rawat, Anish ^b   Huynh, Tam T ^b   Peden, Eric K ^a   Kougias, Panagiotis ^b   Lin, Peter H ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Complication; Deep venous thrombosis; Heparin; Inferior vena cava filter; LMWH; Mechanical prophylaxis; Pharmacological prophylaxis; Pulmonary embolism; Venous thromboembolism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DALTEPARIN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ADRENAL INSUFFICIENCY; ALOPECIA; ARTERY THROMBOSIS; BLEEDING; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPRESSION GARMENT; DISEASE COURSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DYSPEPSIA; GENERAL SURGERY; GYNECOLOGIC SURGERY; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK POPULATION; HIP ARTHROPLASTY; HIP FRACTURE; HUMAN; INFERIOR CAVA VEIN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; KNEE ARTHROPLASTY; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; NEUROSURGERY; OPERATION DURATION; ORTHOPEDIC SURGERY; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PROPHYLAXIS; PROTEIN C DEFICIENCY; PROTHROMBIN TIME; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; SKIN NECROSIS; TRAUMATOLOGY; TREATMENT DURATION; ULCER; UROLOGIC SURGERY; URTICARIA; VASCULAR SURGERY; VEIN THROMBOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; INTERMITTENT PNEUMATIC COMPRESSION DEVICES; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; POLYSACCHARIDES; RISK ASSESSMENT; RISK FACTORS; STOCKINGS, COMPRESSION; SURGICAL PROCEDURES, OPERATIVE; THROMBIN; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 45449106655     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574408315208     Document Type: Review

References (71)

1. Liu JH, Etzioni DA, O'Connell JB, Maggard MA, Ko CY The increasing workload of general surgery. Arch Surg. 2004 ; 139: 423-428.
2. Clagett GP, Reisch JS Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg. 1988 ; 208: 227-240.
3. Geerts W., Ray JG, Colwell CW, et al. Prevention of venous thromboembolism. Chest. 2005 ; 128: 3775-3776.
4. Geerts WH Prevention of venous thromboembolism in high-risk patients. Hematology Am Soc Hematol Educ Program. 2006 ; 6: 462-466.
5. Hirsh J. Current anticoagulant therapy-unmet clinical needs. Thromb Res. 2003 ; 109 (suppl 1). S1 - S8.
6. Muntz JE Deep vein thrombosis and pulmonary embolism in the perioperative patient. Am J Manag Care. 2000 ; 6: S1045 - S1052.
7. Stamatakis JD, Kakkar VV, Sagar S., Lawrence D., Nairn D., Bentley PG Femoral vein thrombosis and total hip replacement. Br Med J. 1977 ; 2: 223-225.
8. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003 ; 124: 386S - 392S.
9. Bick RL, Haas S. Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients. Hematol Oncol Clin North Am. 2003 ; 17: 217-258.
10. Bick RL, Haas SK International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians consensus statement of 1995. International Consensus Statement, 1997. Med Clin North Am. 1998 ; 82: 613-633.
11. Haas S. The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haemostasis. 1996 ; 26 (suppl 2). 39-48.
12. Ageno W., Turpie AG Deep venous thrombosis in the medically ill. Curr Hematol Rep. 2002 ; 1: 73-78.
13. Colwell CW Jr, Spiro TE, Trowbridge AA, Stephens JW, Gardiner GA Jr, Ritter MA Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Enoxaparin Clinical Trial Group. Clin Orthop Relat Res. 1995 ; 321: 19-27.
14. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001 ; 119: 132S - 175S.
15. Clagett GP, Anderson FA Jr, Geerts W., et al. Prevention of venous thromboembolism. Chest. 1998 ; 114: 531S - 560S.
16. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA. 1986 ; 256: 744-749.
17. Reasbeck PG, Guerrini S., Harper J., Sackelariou R., McCaffrey JF Incidence of deep vein thrombosis after major abdominal surgery in Brisbane. Br J Surg. 1988 ; 75: 440-443.
18. Bates SM, Ginsberg JS Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med. 2004 ; 351: 268-277.
19. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126: 338S - 400S.
20. Arcelus JI, Caprini JA, Monreal M., Suarez C., Gonzalez-Fajardo J. The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J Vasc Surg. 2003 ; 38: 916-922.
21. Kelsey LJ, Fry DM, VanderKolk WE Thrombosis risk in the trauma patient. Prevention and treatment. Hematol Oncol Clin North Am. 2000 ; 14: 417-430.
22. Moser KM, LeMoine JR Is embolic risk conditioned by location of deep venous thrombosis ? Ann Intern Med. 1981 ; 94: 439-444.
23. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985 ; 2: 515-518.
24. Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA. 1994 ; 271: 223-225.
25. Galle C., Papazyan JP, Miron MJ, Slosman D., Bounameaux H., Perrier A. Prediction of pulmonary embolism extent by clinical findings, D-dimer level and deep vein thrombosis shown by ultrasound. Thromb Haemost. 2001 ; 86: 1156-1160.
26. Schulman S., Bijsterveld NR Anticoagulants and their reversal. Transfus Med Rev. 2007 ; 21: 37-48.
27. Mosesson MW Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005 ; 3: 1894-1904.
28. Desai UR New antithrombin-based anticoagulants. Med Res Rev. 2004 ; 24: 151-181.
29. Wiles N., Hunt BJ Anticoagulation via anti-Factor Xa inhibition. Lupus. 2006 ; 15: 167-171.
30. Olson ST, Chuang YJ Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med. 2002 ; 12: 331-338.
31. Warkentin TE HIT: lessons learned. Pathophysiol Haemost Thromb. 2006 ; 35: 50-57.
32. Greinacher A. Heparin-induced thrombocytopenia: frequency and pathogenesis. Pathophysiol Haemost Thromb. 2006 ; 35: 37-45.
33. Merli G. Anticoagulants in the treatment of deep vein thrombosis. Am J Med. 2005 ; 118: 13S - 20S.
34. Nutescu EA Emerging options in the treatment of venous thromboembolism. Am J Health Syst Pharm. 2004 ; 61: S12 - S17.
35. Tran AH, Lee G. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. Ann Pharmacother. 2003 ; 37: 1632-1643.
36. Turpie AG, Eriksson BI, Lassen MR, Bauer KA Fondaparinux, the first selective factor Xa inhibitor. Curr Opin Hematol. 2003 ; 10: 327-332.
37. Girolami B., Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost. 2006 ; 32: 803-809.
38. Cosmi B., Palareti G. Oral anticoagulant therapy in venous thromboembolism. Semin Vasc Med. 2003 ; 3: 303-314.
39. Riley RS, Rowe D., Fisher LM Clinical utilization of the international normalized ratio (INR). J Clin Lab Anal. 2000 ; 14: 101-114.
40. Arab D., Lewis B., Cho L., Steen L., Joyal D., Leya F. Antiplatelet therapy in anticoagulated patients requiring coronary intervention. J Invasive Cardiol. 2005 ; 17: 549-554.
41. Dunn CJ, Jarvis B. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs. 2000 ; 60: 203-237.
42. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy. 2001 ; 21: 218-234.
43. Schulman S. The role of ximelagatran in the treatment of venous thromboembolism. Pathophysiol Haemost Thromb. 2005 ; 34 (suppl 1). 18-24.
44. Motsch J., Walther A., Bock M., Bottiger BW Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism. Curr Opin Anaesthesiol. 2006 ; 19: 52-58.
45. Gumulec J., Kessler P., Penka M., et al. Hemorrhagic complications during warfarin treatment. Vnitr Lek. 2006 ; 52 (suppl 1). 79-91.
46. Brigden ML When bleeding complicates oral anticoagulant therapy. How to anticipate, investigate, and treat. Postgrad Med. 1995 ; 98: 153-165.
47. Samama MM, Bara L., Gouin-Thibault I. New data on the pharmacology of heparin and low molecular weight heparins [discussion]. Drugs. 1996 ; 52 (suppl 7). 8-15.
48. Pineo GF, Hull RD Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly. Clin Appl Thromb Hemost. 2005 ; 11: 15-23.
49. Makris M. Management of excessive anticoagulation or bleeding. Semin Vasc Med. 2003 ; 3: 279-284.
50. Shen GX Inhibition of thrombin: relevance to anti-thrombosis strategy. Front Biosci. 2006 ; 11: 113-120.
51. Horton JD, Bushwick BM Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999 ; 59: 635-646.
52. Comerota AJ, Chouhan V., Harada RN, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis [discussion]. Ann Surg. 1997 ; 226: 306-314.
53. Kessler CM, Hirsch DR, Jacobs H., MacDougall R., Goldhaber SZ Intermittent pneumatic compression in chronic venous insufficiency favorably affects fibrinolytic potential and platelet activation. Blood Coagul Fibrinolysis. 1996 ; 7: 437-446.
54. Urbankova J., Quiroz R., Kucher N., Goldhaber SZ Intermittent pneumatic compression and deep vein thrombosis prevention. A meta-analysis in postoperative patients. Thromb Haemost. 2005 ; 94: 1181-1185.
55. Cornwell EE III, Chang D., Velmahos G., et al. Compliance with sequential compression device prophylaxis in at-risk trauma patients: a prospective analysis. Am Surg. 2002 ; 68: 470-473.
56. Goldhaber SZ, Hirsch DR, MacDougall RC, Polak JF, Creager MA, Cohn LH Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). Am J Cardiol. 1995 ; 76: 993-996.
57. Comerota AJ Modern day treatment of acute deep venous thrombosis. Aust N Z J Surg. 1995 ; 65: 773-779.
58. Winemiller MH, Stolp-Smith KA, Silverstein MD, Therneau TM Prevention of venous thromboembolism in patients with spinal cord injury: effects of sequential pneumatic compression and heparin. J Spinal Cord Med. 1999 ; 22: 182-191.
59. Spain DA, Bergamini TM, Hoffmann JF, Carrillo EH, Richardson JD Comparison of sequential compression devices and foot pumps for prophylaxis of deep venous thrombosis in high-risk trauma patients [discussion]. Am Surg. 1998 ; 64: 522-526.
60. Knudson MM, Lewis FR, Clinton A., Atkinson K., Megerman J. Prevention of venous thromboembolism in trauma patients. J Trauma. 1994 ; 37: 480-487.
61. El Sayed HF, Kougias P., Zhou W., Lin PH Utility of retrievable vena cava filters and mechanical thrombectomy in the endovascular management of acute deep venous thrombosis. Vascular. 2006 ; 14: 305-312.
62. O'Shaughnessy DF Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs. Int J Clin Pract. 2004 ; 58: 277-284.
63. Gallus AS, Coghlan DW Heparin pentasaccharide. Curr Opin Hematol. 2002 ; 9: 422-429.
64. Frezza EE, Chiriva-Internati M. Venous thromboembolism in morbid obesity and trauma. A review of literature. Minerva Chir. 2005 ; 60: 391-399.
65. Davidson BL Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients [discussion]. Haemostasis. 2000 ; 30 (suppl 2). 77-81.
66. Pini M., Tagliaferri A., Manotti C., Lasagni F., Rinaldi E., Dettori AG Low molecular weight heparin (Alfa LHWH) compared with unfractionated heparin in prevention of deep-vein thrombosis after hip fractures. Int Angiol. 1989 ; 8: 134-139.
67. Agnelli G., Sonaglia F. Prevention of venous thromboembolism in high risk patients. Haematologica. 1997 ; 82: 496-502.
68. Liu LT, Ma BT Prophylaxis against venous thromboembolism in orthopedic surgery. Chin J Traumatol. 2006 ; 9: 249-256.
69. Melissari E., Stringer MD, Kakkar VV The effect of a bolus injection of unfractionated or low molecular weight heparin during aortobifemoral bypass grafting. Eur J Vasc Surg. 1989 ; 3: 121-126.
70. Swedenborg J., Nydahl S., Egberg N. Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery. Eur J Vasc Endovasc Surg. 1996 ; 11: 59-64.
71. Smith SF, Simpson JM, Sekhon LH Prophylaxis for deep venous thrombosis in neurosurgical oncology: review of 2779 admissions over a 9-year period. Neurosurg Focus. 2004 ; 17: E4.